Alnylam Pharmaceuticals, Inc.
$38.08B- Market cap
- $35.61B
- Debt
- +$4.12B
- Cash
- −$1.66B
Capital structure 90% equity / 10% debt · EV / Revenue 10.25x · EV / EBITDA 63.82x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ALNY stock price vs TECK: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at TECK's multiple
Needs TECK P/E.
Implied fair value · at ALNY's multiple
Needs EPS (TTM), ALNY P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ALNY FY 2025 (ended Dec 31, 2025) · TECK FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 90% equity / 10% debt · EV / Revenue 10.25x · EV / EBITDA 63.82x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ALNYLAM PHARMACEUTICALS, INC. · implied price per share
At least 3 of the last 5 annual free-cash-flow observations must be positive.
TECK RESOURCES LIMITED · implied price per share
The ordinary-share to listed-security ratio could not be verified.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
5.22x
—
Net debt / EBITDA
Leverage against operating earnings
4.13x
11.15x
Cash and equivalents
Liquid reserves on the balance sheet
$1.66B
$5.01B
Total debt
Interest-bearing obligations outstanding
$4.12B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Moderna, Inc.
ALNY vs MRNA
Sarepta Therapeutics, Inc.
ALNY vs SRPT
VERTEX PHARMACEUTICALS INC / MA
ALNY vs VRTX
BioNTech SE
ALNY vs BNTX
ACADIA PHARMACEUTICALS INC
ALNY vs ACAD
CLEVELAND-CLIFFS INC.
ALNY vs CLF
Vale S.A.
ALNY vs VALE
FREEPORT-MCMORAN INC
ALNY vs FCX
SOUTHERN COPPER CORP/
ALNY vs SCCO
NEWMONT Corp /DE/
ALNY vs NEM
$16.97B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.